Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Aug 12;11:7605–7618. doi: 10.2147/CMAR.S212069

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Grywalska et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Time to treatment initiation in patients with chronic lymphocytic leukaemia and detectable [EBV(+)] vs undetectable [EBV(−)] EBV DNA (A) and high or low expression of PD-1 on CD4+, CD8+, and CD19+ cells and in serum (B–E). The classification of PD-1 expression as high or low was based on medians specific for EBV(+) and EBV(−) patients. P-values for log-rank tests are presented for comparisons between EBV(+) and EBV(−) patients (A) and between patients with high or low PD-1 expression within the groups of EBV(+) and EBV(−) patients (B–E). p-values are for log-rank tests, adjusted with Holm’s correction, comparisons between patients with high or low expression within the EBV(−) or EBV(+) groups.

Abbreviations: EBV, Epstein-Barr virus; PD1, programmed cell death protein 1, EBV(−), patients without detectable EBV DNA; EBV(+), patients with detectable EBV DNA; low, expression below median within the EBV(−) or EBV(+) groups; high, expression above median within the EBV(−) or EBV(+) groups.